Sign in

    Kuan-Hung Lin • Wells Fargo

    Kuan-Hung Lin is a Vice President and Equity Research Analyst at Wells Fargo Securities, specializing in the coverage of the fintech and payments sectors. He covers companies including Visa, Mastercard, Fiserv, and PayPal, and has established a reputation for detailed financial modeling and clear investment theses, with a positive track record highlighted by above-average success metrics on investment platforms. Lin began his professional journey in equity research at other major firms before joining Wells Fargo in 2018, progressively advancing to his current leadership role. He holds FINRA Series 7, 63, 86, and 87 licenses and is recognized for his analytical rigor and timely insights in the financial technology arena.

    Kuan-Hung Lin's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership

    Kuan-Hung Lin's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership • Q3 2024

    Question

    Kuan-Hung Lin, on behalf of Yanan Zhu, asked about the company's view on the path to success for FEV1 in its CF program and the key differentiators of ARCT-032 versus Vertex/Moderna's VX-522. He also inquired about the next steps for the ARCT-2303 program.

    Answer

    CEO Joseph Payne highlighted three key differentiators for ARCT-032: its proprietary LUNAR delivery technology, more transparent data sharing, and unique mRNA purification IP. He stated that for the target CF population, any measurable FEV1 improvement would be significant. Payne clarified that the ARCT-2303 data is strategically important to support the KOSTAIVE BLA filing in the U.S. but is not intended to be a standalone commercial product.

    Ask Fintool Equity Research AI

    Kuan-Hung Lin's questions to Voyager Therapeutics Inc (VYGR) leadership

    Kuan-Hung Lin's questions to Voyager Therapeutics Inc (VYGR) leadership • Q2 2024

    Question

    Kuan-Hung Lin of Wells Fargo Securities inquired about the timing of NHP data for the tau siRNA program, the potential for a combination strategy with the antibody, and whether stopping tau spread alone could be sufficient for early-stage patients.

    Answer

    CSO Dr. Todd Carter stated there is no guidance on NHP data timing beyond the planned 2026 IND filing. CMO Dr. Toby Ferguson asserted that due to the high unmet need in Alzheimer's, the lead antibody program would be advanced independently if data are positive, rather than waiting to synchronize it with the gene therapy. He added that stopping tau spread is the program's goal, and achieving that would be a significant clinical success.

    Ask Fintool Equity Research AI